Study demonstrates high patient satisfaction with Azzalure

19 Jun 2019

The results of two studies conducted by pharmaceutical company Galderma (UK) Limited have demonstrated high patient satisfaction for the use of Azzalure (AbobotulinumtoxinA), its botulinum toxin type A product, in the glabellar complex.

The first study, titled the ANGEL study (n=533), took place in 66 centres across four countries, and demonstrated that 97.4% of patients were satisfied or very satisfied with the aesthetic outcome with Azzalure (AbobotulinumtoxinA) at three weeks, and 89.6% were satisfied or very satisfied at four months.

The second study, the APPEAL study (n=135), took place in 13 centres in six countries and highlighted that 97% of patients treated were satisfied or very satisfied three weeks after their first Azzaure (AbobotulinumtoxinA) glabellar line treatment and this figure increased to 99.3% by the third treatment.

Patricia Ramos, brand manager, medical solutions, aesthetic and corrective products, prescription division, Galderma UK and Ireland, said, “It is very important for clinics to have a product that they can trust. These patient satisfaction studies add to the wealth of clinical data that we have demonstrating Azzalure’s (AbobotulinumtoxinA) efficacy.”

Full prescribing information for Azzalure® (AbobotulinumtoxinA) can be found here.


Log-in to post a comment